High Functional P-glycoprotein Activity is More Often Present in T-cell Acute Lymphoblastic Leukaemic Cells in Adults than in Children

There is a distinct difference in prognosis between childhood versus adult acute lymphoblastic leukaemia (ALL). To define whether multidrug resistance (MDR) genes might contribute to this distinction, the expression and functional activity of P-glycoprotein (P-gp) and MDR associated proteins (MRP) were determined with RT-PCR (MDR-1, MRP1, MRP2, MRP3) and flow cytometry (P-gp and MRP). Patient samples were obtained from 36 children and 35 adults with de novo ALL. Of these patients, 38 showed a T-lineage and 33 showed a B-lineage immunophenotype. In the samples, large variability in P-gp activity (0.8-4.9) and MRP activity (1.1-13.9) was observed. Most T-ALL patients with high P-gp activity were adults (89%). The mRNA expression of MDR-1 correlated weakly with P-gp activity. In contrast, MRP activity did not correlate with the mRNA expression of MRP1, MRP2 and MRP3. In T-ALL, a worse overall survival and event-free survival was observed with increasing P-gp activity. P-gp activity had no prognostic impact in B-lineage ALL. In addition, high MRP activity did not influence treatment outcome in either T- or B-lineage ALL. Multivariate Cox regression analysis, showed P-gp activity to be the only unfavourable prognostic factor for overall survival in T-ALL. In conclusion, this study demonstrates the prognostic relevance of P-gp activity in T-ALL. Since the majority of the patients with high P-gp activity were adults, P-gp might contribute to the poor prognosis of adult T-ALL.

[1]  A. Berg,et al.  Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984–1991 , 2000, Leukemia.

[2]  D. Hoelzer,et al.  Recent approaches in acute lymphoblastic leukemia in adults. , 2000, Reviews in clinical and experimental hematology.

[3]  R. Pieters,et al.  In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia , 2000, British journal of haematology.

[4]  E. D. de Vries,et al.  P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  F. Baas,et al.  Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  O. Legrand,et al.  Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. , 1999, Blood.

[7]  D. Keppler,et al.  Export pumps for anionic conjugates encoded by MRP genes. , 1999, Advances in enzyme regulation.

[8]  G. Peters,et al.  MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Philippé,et al.  P‐glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6‐year prospective study , 1999, British journal of haematology.

[10]  P. Jansen,et al.  ATP‐ and glutathione‐dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1 , 1999, British journal of pharmacology.

[11]  S. Cole,et al.  Multidrug resistance mediated by the ATP‐binding cassette transporter protein MRP , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[12]  E. van den Berg,et al.  Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  O. Legrand,et al.  Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. , 1998, Blood.

[14]  H. Prentice,et al.  The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties , 1998, Leukemia.

[15]  R. Pieters,et al.  Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. , 1998, Blood.

[16]  E. Vellenga,et al.  Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a ‘pre‐induction’ course for rapid tumour reduction: preliminary results on 66 patients , 1998, British journal of haematology.

[17]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[18]  J. Perentesis Why is age such an important independent prognostic factor in acute lymphoblastic leukemia? , 1997, Leukemia.

[19]  G. Reaman,et al.  Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. , 1996, Blood.

[20]  P. Sonneveld,et al.  Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. , 1996, Blood.

[21]  E. Wattel,et al.  Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: absence of correlation with response to treatment. , 1995, Leukemia.

[22]  S. Proctor,et al.  Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia , 1995, British journal of haematology.

[23]  D. Keppler,et al.  The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. , 1994, The Journal of biological chemistry.

[24]  P. Sonneveld,et al.  Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. , 1993, Blood.

[25]  O. Fardel,et al.  Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. , 1993, Blood.

[26]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[27]  C. Jasmin,et al.  Concepts of remission, curability and lineage involvement in relationship to the problems of minimal residual leukaemia. , 1991, Bailliere's clinical haematology.

[28]  B. Dörken,et al.  Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. , 2000, Haematologica.

[29]  R. Page,et al.  Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines. , 2000, Anticancer research.

[30]  J. Philippé,et al.  Discordance of P-glycoprotein expression and function in acute leukemia. , 1999, Advances in experimental medicine and biology.

[31]  P. Musto,et al.  Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression. , 1997, Haematologica.

[32]  Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique. , 1996, Blood.

[33]  A. Ford-hutchinson,et al.  Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. , 1989, Canadian journal of physiology and pharmacology.